» Articles » PMID: 33479342

Positive Expectations Predict Improved Mental-health Outcomes Linked to Psychedelic Microdosing

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jan 22
PMID 33479342
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic timepoints, spanning a core four-week test period. Eighty-one participants completed the primary study endpoint. Results revealed increased self-reported psychological well-being, emotional stability and reductions in state anxiety and depressive symptoms at the four-week primary endpoint, plus increases in psychological resilience, social connectedness, agreeableness, nature relatedness and aspects of psychological flexibility. However, positive expectancy scores at baseline predicted subsequent improvements in well-being, suggestive of a significant placebo response. This study highlights a role for positive expectancy in predicting positive outcomes following psychedelic microdosing and cautions against zealous inferences on its putative therapeutic value.

Citing Articles

Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry.

Aday J, Barnett B, Grossman D, Murnane K, Nichols C, Hendricks P Psychedelic Med (New Rochelle). 2025; 1(3):150-165.

PMID: 40046566 PMC: 11661494. DOI: 10.1089/psymed.2023.0013.


Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.

Kinderlehrer D Neuropsychiatr Dis Treat. 2025; 21:141-155.

PMID: 39897712 PMC: 11787777. DOI: 10.2147/NDT.S500337.


Psychological effects of psychedelics in adolescents.

Izmi N, Carhart-Harris R, Kettner H Front Child Adolesc Psychiatry. 2025; 3():1364617.

PMID: 39816600 PMC: 11732004. DOI: 10.3389/frcha.2024.1364617.


Expectations regarding school decreases emotional distress among college students in Western China: the buffering role of physical exercises.

Su D, Huang L, Zou H, Zhang L, Feng Y Front Public Health. 2024; 12:1412199.

PMID: 39568599 PMC: 11576314. DOI: 10.3389/fpubh.2024.1412199.


Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study.

Enriquez-Geppert S, Krc J, OHiggins F, Lietz M Philos Trans R Soc Lond B Biol Sci. 2024; 379(1915):20230095.

PMID: 39428872 PMC: 11513162. DOI: 10.1098/rstb.2023.0095.


References
1.
Glick M . Placebo and its evil twin, nocebo. J Am Dent Assoc. 2016; 147(4):227-8. DOI: 10.1016/j.adaj.2016.02.009. View

2.
Roseman L, Nutt D, Carhart-Harris R . Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Front Pharmacol. 2018; 8:974. PMC: 5776504. DOI: 10.3389/fphar.2017.00974. View

3.
Hartogsohn I . The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity. Front Neurosci. 2018; 12:129. PMC: 5845636. DOI: 10.3389/fnins.2018.00129. View

4.
Carhart-Harris R, Kaelen M, Whalley M, Bolstridge M, Feilding A, Nutt D . LSD enhances suggestibility in healthy volunteers. Psychopharmacology (Berl). 2014; 232(4):785-94. DOI: 10.1007/s00213-014-3714-z. View

5.
Kube T, Rief W . Are placebo and drug-specific effects additive? Questioning basic assumptions of double-blinded randomized clinical trials and presenting novel study designs. Drug Discov Today. 2016; 22(4):729-735. DOI: 10.1016/j.drudis.2016.11.022. View